Back to Search
Start Over
Reply
- Source :
- Journal of the American College of Cardiology. 74:826
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- We appreciate the comments by Baker and colleagues on our paper [(1)][1]. We described that empagliflozin ameliorates adverse cardiac remodeling, enhances systolic function, switches myocardial fuel utilization, and improves myocardial energetics in a nondiabetic heart failure (HF) model. Baker and
- Subjects :
- Myocardial energetics
medicine.medical_specialty
business.industry
Systolic function
030204 cardiovascular system & hematology
medicine.disease
03 medical and health sciences
0302 clinical medicine
Internal medicine
Heart failure
medicine
Empagliflozin
Cardiology
030212 general & internal medicine
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- ISSN :
- 07351097
- Volume :
- 74
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.doi...........c44b642548b30cdff7b7856e29afe43f
- Full Text :
- https://doi.org/10.1016/j.jacc.2019.06.017